torcetrapib

(redirected from CETP inhibitor)

torcetrapib

A cholesterol ester transfer protein (CETP) inhibitor drug that has been shown capable of substantially increasing levels of high density lipoprotein (HDL) cholesterol. A major trial of this drug in conjunction with atorvastatin was stopped by Pfizer at the end of 2006.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Frishman, "Evacetrapib: another CETP inhibitor for dyslipidemia with no clinical benefit," Cardiology in Review, vol.
And Amgen announced in September that it would pay at least $300 million to buy Dezima Pharma, a privately held Dutch company that has a CETP inhibitor ready to enter the final stage of clinical testing.
Amgen gains itsTA-8995 oral, once-daily CETP inhibitor in development for use in patients with mild dyslipidemia.
The team at Forbion recognized early on the potential of TA-8995, an oral, once-daily CETP inhibitor and helped to found, fund and staff the company, including in-licensing this lead asset from Mitsubishi Tanabe Pharma Corp.
The potential future therapeutic options for targeted Lp(a) control include cholesterol-ester transfer protein inhibitors (CETPI), anti-sense oligonucleopeptides (ASO) and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK-9I) and L-carnitine.22,23 The CETP inhibitor Anacetrapib has been shown to reduce Lp(a) plasma levels by up to 50%.24 The ASO Mipomersen lowers Lp(a) by up to 50% in phase 2 trials with single injections given fortnightly.25 Maximum reductions occur after 3-6 months of continuous therapy, and slowly return to baseline after cessation of therapy.25 The PCSK-9I, AMG-145, has similar effects on Lp(a) levels with once monthly injections.26 Carnitine supplementation therapy in doses of up to 1gm daily leads to 10-15% reduction (Table-2).23,24
Results of another study of a CETP inhibitor, dalcetrapib, were presented at the American Heart Association annual meeting in November 2012 and published simultaneously in the New England Journal of Medicine.
18 November 2010 - US pharmaceutical company Merck and Co Inc (NYSE: MRK) said yesterday that its investigational CETP inhibitor anacetrapib has met safety and efficacy endpoints in patients with coronary heart disease (CHD) in a Phase III DEFINE (Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib) study.
Indeed, the drug company Pfizer, based in New York, is currently testing a CETP inhibitor as a promoter of heart health.
The first CETP inhibitor, torcetrapib, proved unsuccessful because it increased levels of aldosterone, a hormone that increases blood pressure.
Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.